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The current and future applications of genomics to the practice of preventive oncology are being
impacted by a number of challenges. These include rapid advances in genomic science and technology
that allow massively parallel sequencing of both tumors and the germline, a diminishing of intellectual
property restrictions on diagnostic genetic applications, rapid expansion of access to the internet which
includes mobile access to both genomic data and tools to communicate and interpret genetic data in a
medical context, the expansion of for-proﬁt diagnostic companies seeking to monetize genetic
information, and a simultaneous effort to depict medical professionals as barriers to rather than
facilitators of understanding one’s genome. Addressing each of these issues will be required to bring
“personalized” germline genomics to cancer prevention and care. A profound future challenge will be
whether clinical cancer genomics will be “de-medicalized” by commercial interests and their advocates,
or whether the future course of this ﬁeld can be modulated in a responsible way that protects the public
health while implementing powerful new medical tools for cancer prevention and early detection.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Whether or not it was ﬁrst said by atom-splitter Niels Bohr or
splitter-ball catcher Yogi Berra, we all agree “it’s tough to make
predictions—especially about the future.” In the concluding section
of this monograph on the current status of predictive cancer
genomics, it is appropriate to ponder the future of this transla-
tional ﬁeld of medical science. As will also be addressed here, it is
particularly instructive for the providers and consumers of the
rapid advances in genomics and medicine to make their own
predictions of the impact of “personalized genomics” on preven-
tive oncology.
This effort to encourage introspection is meant to highlight the
sea change that is shaping the way genomic predictive markers
have been integrated in the practice of “precision medicine.” The
elements of this sea change are multifold and have constituted a
virtual “perfect storm” which is now raining down on the clinical
practice of cancer genomics. As will be discussed here, these
factors include the rapid advances in genomic science and tech-
nology that allow massively parallel sequencing of both tumors
and the germline [1,2], a landmark shift in interpretation ofInc. This is an open access article u
PH, Chief, Clinical Genetics
iology and Genetics Program,
ancer Center, 1275 York Ave,
46) 888 4081.statutes bearing on intellectual property and diagnostic applica-
tions of germline genetic discoveries [3], rapid expansion of access
to the internet, including mobile access to both genomic data and
tools to interpret these data in a medical context, the expansion of
for-proﬁt genomic diagnostics—some masquerading as “recrea-
tional genomics,” and a potentially worrisome effort to depict
medical professionals as barriers to rather than facilitators of
understanding one’s genome. Each of these factors will impact
how the discipline of predictive and preventive oncology is able to
shape the translation of genomic technologies in the most respon-
sive and responsible way. Here, the challenges and potential
conﬂicts in bringing “personalized genomics” to oncology will
constitute the primary focus. I will build on a framework devel-
oped in a prior essay on this topic [4], updating and expanding
these observations based on recent developments in the clinic, in
translational research, in the courts, and in the economic and
social infrastructure that impact how cancer patients and those at
risk for cancer have access to and can beneﬁt from genomic
information.2. Shifting paradigms in cancer genomics
2.1. Causative events, consequences, and emerging strategies
In his classic monograph “The Structure of Scientiﬁc Revolu-
tions” [5], the historian of science Thomas Kuhn coined the term
“paradigm shift” to characterize periods of sudden departure fromnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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practice of science in a fundamental, revolutionary way. To a real
extent the rapid pace of the “genetic revolution” has impacted
medicine. Perhaps in no other area has this change been more
dramatically felt than clinical cancer genomics.
The preceding chapters of this monograph have updated our
current knowledge of inherited mechanisms of cancer suscepti-
bility. They have presented new information about genotype and
phenotype, risk prediction, and targeted intervention. However,
this monograph can only give hints at what lies ahead, since the
major forces that will drive changes in clinical genomics are only
now coming into focus. Thomas Kuhn stated that to meet the bar
of a paradigm shift, the new advances must be "sufﬁciently
unprecedented to attract an enduring group of adherents away
from competing modes of scientiﬁc activity." He predicted that a
true paradigm shift would be "sufﬁciently open-ended to leave all
sorts of problems for the redeﬁned group of practitioners to
resolve." Here, we will argue that the factors driving the paradigm
shift in cancer genomics are not only on the verge of changing the
medical model for delivering cancer genetic information but of
replacing it entirely.2.1.1. Consequences of current generation DNA sequencing
Compared to Sanger capillary-based sequencing, massively
parallel sequencing, touted as “next-generation sequencing”
(NGS), is now part of current generation practice. NGS employs
simultaneous sequencing reactions detected automatically, pro-
ducing millions of sequence calls per instrument run, at a
signiﬁcantly lower expense. Recent advances have increased the
number of nucleotides per sequence read (or read lengths) and
lower cost and greater base-calling accuracy [1]. These technolo-
gies have been applied to sequencing of exomes, entire genomes,
and exons and splice region sequences of selected genes. The
research impact of NGS technologies on the pace of new syndrome
identiﬁcation has been remarkable. By sequencing relatively few
members of families with recurrent and unexplained malignancies
it has been possible over just the past few years to identify over a
dozen new cancer syndromes (Table 1). Only some of these new
syndromes have been included in the preceding sections of this
monograph, as these discoveries are so recent that precise geno-
type–phenotype correlations have yet to be established. As an
example of the challenges of clinical translation posed by these
NGS discoveries, we described two new syndromes of predisposi-
tion to childhood acute lymphoblastic leukemia [6,7], both caused
by inherited mutations of transcription factors. While there was
compelling functional biological evidence of “causation” behind
the association of these germline mutations and the familial
occurrences of leukemia, both syndromes demonstrated incom-
plete penetrance, and for both there was no proven preventive
intervention other than pre-implantation genetics to halt trans-
mission of the trait. In contrast, we have recently employed NGS to
discover a novel mechanism of susceptibility to breast cancer due
to a mutation in the nucleotide excision repair pathway, which
does provide a potential rationale for targeted therapy [8].
In addition to their role powering whole genome discovery,
NGS technologies have also impacted the rapid diagnosis of known
syndromes by utilizing “capture” of exons and exon–intron splice
regions of dozens of cancer predisposition genes, all analyzed
simultaneously, as part of a new wave of multiplexed diagnostic
panels [9]. As will be discussed, this technological innovation has
stimulated the appetite of both providers and consumers of
genetic tests, in favor of “prix ﬁxe” menus of multiple gene tests
at costs lower than that of the old “a la carte” one-at-a-time menu
of phenotype-directed genetic analysis.2.1.2. Fallout of the end of gene patenting
Just as NGS technologies began to generate novel syndromic
discoveries of potential diagnostic value, the US Supreme Court
ruled that isolated genomic DNA was not patent-eligible under
section 101 of the Patent Act. The court, however, let stand patents
for cDNA, an approach which some of us accurately predicted
before the decision, and which we argued would have a gradual
impact on the practice of preventive oncology [3]. The opinion
written by Justice Thomas was unanimous and brief. The oral
argument, was notable for the apparent and very limited under-
standing of the Justices and the US Solicitor General of basic
concepts of genetics (eg, the difference between DNA and RNA),
and the use of nonscientiﬁc metaphors, involving trees, baseball
bats, etc. The late Justice Scalia wrote that he agreed with the
majority opinion even though he admitted he did not feel
educated enough on the topic to sign the recitation of “the details
of molecular biology.” Within a few days of the decision, as NY
Times reporter Andrew Pollack sought conﬁrmation from many of
us that it would be a very short time before academic and for-
proﬁt genetic testing companies would make available NGS for
panels including BRCA1/2 [10], many also expressed concern that
broad deployment of these multigene panels was premature in the
absence of regulatory oversight of quality of testing, evidence of
clinical utility, and strategies to interpret genetic variation [9].
2.1.3. Awash in variants of familiar and novel genes
Despite the warnings, the rush to multigene panels left clini-
cians coping with interpretations of reports of variants of
unknown signiﬁcance (VUS), with such ﬁndings as frequent as
10%–90% depending on gene and panel [11]. Of more concern,
anecdotal experience revealed some not ideally educated health
practitioners recommending preventive surgeries following VUS
detection. And even more challenging, the multiplex panels
included genes for which mutations were only known to be
associated with low to intermediate penetrance, and genes for
which mutations had unclear clinical utility and were previously
not recommended for clinical testing. For example CHEK2, recom-
mended as of unclear clinical utility in the era of single gene
testing [12], was now routinely included in multigene panels.
Valiant efforts were made to catalogue current knowledge of
disease speciﬁc gene of varying penetrance [13]. As new genes
came to be discovered by NGS strategies (represented in Table 1),
they often were added to existing panels, even in the absence of
data on associated phenotypes and penetrance.
2.1.4. Initial response of federal agencies and the academy to the
genomic tsunami
Just as the “tsunami” from the perfect storm of NGS break-
throughs, internet marketing, and the lifting of intellectual prop-
erty restrictions hit clinical oncology, one federally supported body
charged with interpreting the evidence basis for genomic diag-
nostics, including those for cancer susceptibility, experienced a
95% budget reduction. This group, called The Evaluation of
Genomic Applications in Practice and Prevention (EGAPP) Initia-
tive, funded largely by the Center for Disease Control, had
produced a number of evidence reviews bearing on cancer [14–17].
However, EGAPP was not to be fully available for the sudden
commercial proliferation of multigene panels in cancer risk test-
ing. To address the most pressing need for cross-sectional data-
bases, to document genetic variation and curation, and in the
absence of a uniﬁed strategy from the for-proﬁt laboratories to
address the consequences of premature deployment of multigene
panels, spontaneous initiatives were launched by other stake-
holders. The BRCA Global Challenge was organized by a combina-
tion of governmental, commercial, and academic groups to seek to
Table 1
Impact of next generation sequencing on the discovery of novel cancer predisposition syndromes.
Familial Cancer Syndrome NGS Gene Cases used to identify
Pancreatic cancer
Jones et al., Science 2009 [70] Exome PALB2 1 affected familial pancreatic cancer
Roberts et al., Can Disc 2012 [71] WGS ATM WGS/Exome:16/22 affecteds 6/10 families
Pheochromocytoma
Comino-Mendez et al., Nat Gen 2011 [72] Exome MAX 3 affecteds from 3 families
Wilms Tumor
Mahamdallie et al., Nat Genet 2015 [73] Exome REST 4 families
AML/MDS
Ostergaard et al., Nat Gen 2011 [74] Exome GATA2 3 unrelated affecteds (2 w/ familial)
Familial Myeloid
Saliba et al., Nat Genet 2015 [75] Exome ATG2B GSKIP 4 related kindreds
Familial Melanoma
Yokoyama et al., Nature 2011 [76] WGS MITF 1 affected with familial melanoma
Horn et al., Science 2013 [77] Tar Seq TERT 4 affecteds/1 unaffected in 1 kindred
Mesothelioma/uveal
Testa et al., Nat Gen 2011 [78] Exome BAP1 2 Kindreds
melanoma/renal
Farley et al., Mol Ca Res 2013 [79] 1/83 kindreds
Colorectal adenomas/ca
Palles et al., Nat Genet 2013 [80] WGS POLE, POLD1 20 affecteds /15 families
Weren et al., Nat Genet 2015 [81] Exome NTHL1 51 affecteds/48 families
Non Medullary Thyroid
Gara et al., NEJM 2015 [82] Exome HABP2 7 affected 1 kindred
Breast Cancer
Park et al., AJHG 2012 [83] Exome XRCC2 5 affecteds from 2 families
Park et al., BCRT 2011 [84] Exome FAN1 4 early-onset multiple-case families
Ruark et al., Nature 2013 [85] TarSeq PPMD1 1,150 with breast cancer þ/- ovarian
Cybulski et at., Nature Genet 2015 [86] Exome RECQL 7 cases Quebec, 30 in Poland
Vijai J et al., Cancer Disc [8] Exome ERCC3 46 early-onset and 13 familial breast cancer probands
Ovarian cancer
Rafnar et al., Nat Genet 2011 [87] WGS BRIP1 457 Icelanders
ALL
Shah et al., Nat Genet 2013 [6] Exome PAX5 2 kindreds
Noetzli Nat Genet [88], Zhang Nat Genet [89], Topka PLoS Genet 2015 [7] Exome ETV6 Multiple kindreds
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Human Genome Research Institute organized investigators
through ClinGen [19] to form a Cancer Working Group to establish
databases and strategies to curate key cancer susceptibility genes
such as PTEN, and deposit these data into ClinVar [20]. At the same
time, we at Memorial Sloan Kettering Cancer Center, and col-
leagues at the University of Pennsylvania, the Mayo Clinic and the
Dana Farber Cancer Institute, built an on-line portal open to all
individuals who had multigene panel testing. This initiative, called
the Prospective Registry for Multiplex Testing (PROMPT) aimed to
create a cohort for study of penetrance and variants, and has over
two thousand participants and is growing. The effort was joined by
the seven largest commercial laboratories, which added onto their
reports the link for patients with VUS and/or mutations in
intermediate-penetrance genes to consider joining this registry
[21]. Indeed, we strongly encourage all oncologists, genetic coun-
selors, and others ordering multigene panel tests to provide their
patients with links to join the PROMPT registry (www.
promptstudy.org) An immediate observation of the PROMPT
registry, was a 26% rate of divergent reports among the commer-
cial laboratories [22]. Such a ﬁnding is consistent with reports at
recent meetings of the Clinical Sequencing Exploratory Research
groups of the NHGRI documenting divergent results of “bake off”
exercises of carefully blinded variant curation comparisons among
experts [23]. These ﬁndings underscore the risks of the premature
deployment of these technologies.2.1.5. Response from payers
Some third-party payers had already recognized that the
increasing cost of cancer diagnostic testing could be manipulatedby decreasing access. Based on perceptions of the need for
continued physician education in the realm of cancer genetic
testing and the effectiveness of genetic counseling, one insurance
carrier put in place policies to deter licensed oncologists from
ordering BRCA tests. In the name of “quality improvement,” such
tests were approved only if patients were ﬁrst screened by genetic
counselors who were either funded by the insurer, or accessed via
directed consultation to determine if a test was indicated [24,25].
This strategy established a de facto ﬁlter to access to cancer genetic
testing [26] and also raised a potential challenge of restraint of the
practice of cancer medicine by oncologists seeking to order genetic
tests to guide therapy (eg, PARP inhibitors) as well as prevention
[25]. With the planned expansion of these policies, a prediction for
the future is a confrontation between practitioners and at least one
large payer over the issue of scope of practice and access to care.2.1.6. Less may be more in germline genomic scans
The advent of multigene testing served to galvanize some
payers to seek to limit their use, on the basis of the unproven
clinical utility of all gene tests included on the panels [27]. Within
the “expert committees”, such as the National Comprehensive
Cancer Network (NCCN), there has been healthy and ongoing
debate and efforts to ensure that guidelines, monitored closely
by insurers, reﬂect the rapidly changing evidence base. At present
and going forward, there will be a trend to reimburse only those
tests for which there is proven clinical utility, with clinicians and
patients facing a web of different thresholds for testing varying by
laboratory or type of third-party provider.
There is also an emerging “push back” among both patients and
providers against the obligate prix ﬁxe model of multiplex testing.
K. Ofﬁt / Seminars in Oncology 43 (2016) 615–622618It was a hallmark observation of clinical genetics that from a third
to half of patients counseled for suspected Li Fraumeni syndrome
would defer p53 testing. TP53 testing, if offered as an option, was
not desired for inclusion on the test panel by a proportion of
patients offered multi-gene testing (Robson M, personal commu-
nication). Many clinicians would also like to be able to exclude or
include speciﬁc genes depending on phenotype, and lack of clinical
utility for some genes on “panels” (eg, CDH1 in non-lobular breast
cancer). Thus, another prediction for the future is the movement
toward physician- and provider-selected panel compositions.
Going forward, increasing numbers of labs are offering “cus-
tom” gene panels, in most cases running the larger panels
internally, but “ﬁltering” reported results only to what is
requested. This strategy allows both consumers and genetics
professionals to request only those tests that have evidence of
clinical utility. Clinicians (and their patients) can then defer other
results until data on clinical utility emerges, thus reserving for the
laboratories the future option to report additional results—and
perhaps recover costs. Such a strategy of maintaining identiﬁed
potentially actionable genomic data will likely require documented
prospective consent. Unlike the “diagnostic odyssey” that often
justiﬁes whole-exome testing in the evaluation of neurodevelop-
mental and other pediatric disorders, as will be documented by
NHGRI-funded studies in progress, the burden of “duty to warn” of
non-cancer predispositions raises signiﬁcant challenges for adults
subjected to whole-exome germline tumor–normal screens
[28,29].
2.2. The tale of two genomes, screening, and pharmcogenomics
Just as NGS technology allowed multiplex gene-panel testing,
the second wave of the NGS tsunami impacted the clinical
application of genome-wide re-sequencing of tumors to guide
targeted therapies. In the process, the patients’ “normal” or
inherited DNA is typically also scanned, raising immediate medical
as well as ethical challenges [28,29]. While one commercial
laboratory and many academic laboratories purposely avoid
sequencing normal DNA as a comparator for the tumor DNA, it is
now clear that inclusion of such reference normal sequence adds
to the sensitivity of the assay [30]. Initial tumor sequencing
strategies have simply “subtracted” inherited variation from the
tumor genomic reports, resolving some of the ethical and medical
complexity surrounding consent for familial cancer risk testing at
time of diagnosis of malignancy [28]. Anonymized retrospective
analyses of tumor-normal genomic data from several large centers
[30–34], published at the outset of 2016 (Table 2) demonstrated
3%–13% actionable germline ﬁndings, indicating that within the
germline compartment of tumor–normal sequence data, is a trove
of clinically relevant information. A number of other studies will
appear in the next year that will include prospective series thatTable 2
Recent tumor-normal sequencing studies, including germline ﬁndings that are
actionable [30–34].
Institutional
series [28–32]
Johns
Hopkins
University
University
of
Michigan
Memorial
Sloan
Kettering
St. Jude
Children’s
Research
Hospital
Baylor
College
of
Medicine
No. sequenced 815 91 1,566 1,120 150
No. of
germline
actionable
ﬁndings (N)
27 9 198 95 13
Germline
actionable
ﬁndings (%)
3% 10% 12.6% 8.5% 8.6%will identify signiﬁcant proportions of cases of breast, colon,
ovarian, prostate, renal, and other cancers with inherited muta-
tions detected by “agnostic” tumor–normal testing. It will be
critical to determine whether phenotype-directed germline testing
would have led to the detection of the substantial fraction of
inherited variants seen in such “agnostic” genomic scans. These
studies will also allow for targeting treatment as well as preven-
tion, as already evidenced by the 12% fraction of prostate cases
with inherited mutations of DNA repair genes [35]. Included in the
DNA repair genes are DNA homologous repair genes potentially
amenable to therapy with PARP inhibitors, as well as subsets
with Lynch associated mutations, potentially amenable to
immunotherapy.
These ﬁndings have led our institution to collect tumor–normal
DNA sequence in the setting of a consent process which explains
that if inherited markers of cancer susceptibility are found, and if
the patient desires, these results will be communicated in the
context of genetic counseling. This communication of germline
ﬁndings allows a tiered approach to informed consent for NGS
studies (Fig. 1) and will provide germline cancer risk assessment at
the same time as tumor mutations are assessed as therapeutic
targets. Thus, one of the evident future scenarios for clinical cancer
genomics is a “tale of two genomes” where both tumor and
inherited information is made available to all cancer patients at
the time of diagnosis. This tumor–normal testing will result in a
“cascade” of genomic information to unaffected relatives for use in
targeted prevention (and even reproductive planning), while
tumor derived information from the proband is used to target
therapy.2.2.1. Population screening
It was evident even at close of the ﬁrst wave of cancer
predisposition gene discovery in the 1990s that genetic testing
could lead to early diagnosis and prevention of many breast,
ovarian, colon, thyroid, stomach, and pediatric cancers [36]. For
breast and ovarian cancer, evidence supported decreased mortality
due to these tumors [37]. However, current guidelines limit BRCA
testing to those with strong family histories of breast or ovarian
cancer and/or early age of onset of disease, “triple-negative” breast
cancer affected before age 60, those with invasive ovarian cancer,
and individuals of Ashkenazi origin with breast cancer [38]. The US
Preventive Services Task Force has not endorsed population-based
BRCA screening [39,40]. Nonetheless, with the advent of NGS
technologies, during the past year some have come to call for
population-based BRCA testing [41,42]. A thoughtful discussion
concluded that population-based BRCA screening would likely
accentuate health access and resource limitations, particularly for
minority women, and could result in false-negative results in the
absence of professional genetic counseling, false positives due to
incorrect interpretation of variants of uncertain signiﬁcance, as
well as other potential harms due to psychosocial factors [43].
However, a different argument can be made for genetic screening
in “founder” populations such as is the Ashkenazi Jews, where we
described a single BRCA2 mutation present in over 1%, and 1 in 40
individuals carrying one of three BRCA1/2 mutations [44–47].
Strikingly, 26%–55% of individuals with BRCA mutations will be
missed if testing is limited to criteria based on family history
[48–54], and some of these cases invariably will represent poten-
tial lives lost if BRCA-based surgical or medical interventions are
not initiated [55]. Indeed, BRCA population-based screening in
Ashkenazi Jews has been performed in pilot studies [56,57] and is
cost-effective; the cost per cancer detected was nearly 40-fold less
expensive in Ashkenazi Jews compared to non-Ashkenazi Jews
[58]. A group of us have begun work to initiate in the near future a
population-based study to offer BRCA testing to Ashkenazi Jews in
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Fig. 1. Next-generation sequencing of tumors with incorporation of incidental germline ﬁndings (adapted from Stadler, 2014 [1]).
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priate counseling [59]. The results of this trial may offer important
guidance for the integration of genomics into mainstream medical
practice. Large-scale studies are also underway to provide genomic
sequencing in 100,000 individuals [60], as well as other studies as
part of federal and academic “precision medicine” initiatives.2.2.2. The belated arrival of pharmacogenomics
Pharmacogenomics assesses inherited (or acquired) genetic
abnormalities to predict treatment response or outcome. Despite
anticipation a decade ago of its explosive impact on the ﬁeld of
oncology, the clinical utility established by pharmacogenetic
studies in cancer has been limited to a handful of variants linked
to treatment response (eg, UGT1A1, CYP2D6) and a plethora of
genome-wide studies of response and toxicity [61], including some
with a high level of interest in clinical application [62]. Recently
rare variants have been associated with cardiotoxicity following
anthracycline-based chemotherapy, an issue of pressing clinical
relevance for those planning adjuvant and/or curative treatments
of a number of hematopoietic and solid tumors. One such ﬁnding
was that a coding variant in RARG appeared to be associated with
cardiotoxicity following childhood cancer [63]. A major challenge
of pharmacogenomic studies remains the need for large numbers
of well-phenotyped patients treated with the same dosage and
type of chemotherapy. Successful pharmacogenomic studies con-
ducted during in vitro cell-based models, with conﬁrmation of
ﬁndings in vivo, now provide an important approach to move this
ﬁeld forward, with initial genome wide association study data
providing identiﬁcation of single-nucleotide polymorphisms pre-
dicting, for example, response to platinum in patients with
urothelial (or other) carcinoma, and in colorectal and prostate
cancer [58]. One would clearly anticipate that an inevitable result
of the era of expanded tumor–normal sequencing, will be the
identiﬁcation of variants associated with treatment outcome and
toxicity.
2.3. Concluding comments on the “de-medicalizing” of cancer
genomic testing
As mentioned at the outset, a “perfect storm” of factors,
including scientiﬁc discovery of new cancer susceptibility genes,
the availability of large scale genomic sequence data unfettered byintellectual property limitations, mobile access to the internet,
entrepreneurial investment in for-proﬁt genomics, and exhorta-
tions to end “genetic exceptionalism” by non-clinician enthusiasts
of direct to consumer genetic testing, have led to a view of medical
professionals as barriers to rather than facilitators of understand-
ing one’s genome. Each of these factors will impact predictive and
preventive oncology.
To illustrate the scope of these challenges to predictive oncol-
ogy, Table 3 lists potential future scenarios for clinical cancer
genomics. Underlying the future path chosen will be a need to
understand the conﬂation of terminology that seeks to cast health
professionals as barriers to rather than trusted guides to accessing
the personal genome. On one hand, there is a clear trend in
biomedical disciplines for greater empowerment and participation
of the patient in all aspects of research and care [64]. Medical
records will increasingly reﬂect genomic data [65]. At the same
time, while some have cast doubt on the speed of the impact of
“precision oncology” [66], and characterized this set of changes as
part of the continuum of positive but “disruptive” technologic
innovation [67], most would predict that in person, phenotype-
driven genetic testing will soon be replaced. Instead of extended
genetic counseling sessions, there will be ”automated” pretest
introduction to panels of genes, with results provided by “alter-
native” strategies to decrease reliance on in-person communica-
tion. However, it is unclear as to the tempo of this transition. Will
this paradigm shift be complete by 2020? Or 2040? Why does this
matter?
Certainly the tempo of this shift to “high throughput genetic
counseling and testing” matters economically for those for-proﬁt
entrepreneurs who have invested. Already some genetic testing
companies have failed, while other large corporations, particularly
search engines and information technology ﬁrms, have committed
substantial sums toward online delivery of “personalized
genomics.” Other than its economic fallout, the tempo of this
transition to more direct, unﬁltered access to individual genomic
sequence matters for society. Indeed, the public health may be as
much at risk from the premature deployment of de-medicalized,
commercialized testing for genetic predisposition, as it is from the
health threats of the syndromes of cancer predisposition them-
selves. According to this view, while claiming to “empower”
individuals to seize rightful control of their personal genomes,
for-proﬁt companies, abetted by some fervent but clinically inex-
perienced basic scientists, are “commoditizing” the genome. By
Table 3
2020 Foresight: Future paradigms for clinical cancer genomics.
If you would be willing to anonymously reply to this opinion survey online, please go to https://www.surveymonkey.com/r/6XHXS5J. Results may be posted in the future.
In your opinion, which response best characterizes the future state of predictive cancer genomics:
1) In 2020, most germline cancer genetic testing will be delivered
a) By cancer genetic health care professionals using traditional forms of genetic counseling
b) By a variety of health care professionals ordering tests on-line, with blood or saliva samples sent and results received online or in person, and reimbursed by
carriers.
c) By individuals via direct-to-consumer testing, largely self-paid, with results discussed with a health care provider only if initiated by the consumer
d) In the context of treatment selection, limited by third party payers, and with results delivered as any other medical test.
2) By 2020, the assessment of the patient newly diagnosed with cancer, for the largest number of cases, will include
a) Tumor only testing for mutations that are shown to target therapies
b) Tumor-normal testing including germline risk assessment at the same time
c) Tumor-normal exome/genome/transcriptome testing with reporting of all inherited ﬁndings, including non cancer risks
3) By 2020, pre-implantation genetic diagnosis for cancer predisposition
a) Will be used at about the same frequency as today
b) Will be used much more often and reimbursed by carriers
c) be impacted by direct germline “editing,” prohibited in the US, but obtained abroad.
d) Will be routinely included as part of “ﬁtness” screens offered to all reproductive age couples, with deﬁned indications for reimbursement by carriers
4) By 2020, pharmaco-genomic testing for cancer drug and dose selection
a) Will be utilized uncommonly as drug choices and dosing will be based on other factors
b) Will be routinely performed as part of pretreatment assessment of the cancer patient
c) Will be performed commonly but after initiation of treatment in the assessment of severe toxicity in selected cancer patients
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the individual and the right to “know” their personalized genome,
commercial companies and their distinguished (and sometime
co-invested) consultants, are de facto seeking to exclude the
one group with an explicit ﬁduciary responsibility to the
patient, family, and individual. When independent health care
providers- physicians, genetic counselors, and other health care
providers- are removed from the individual’s quest for genetic
self-knowledge, there may be no one else to turn to except an
employee of the testing organization itself, incentivized to proﬁt
from increased utilization of its services.
In de-medicalizing genomic direct to consumer testing, there
was an initial appeal to the broader concept of “recreational
genomics” [68]. However recreational cancer genetic testing may
be more similar to recreational drug use than commercial pur-
veyors would advertise. The important distinctions lay in the
medical implications of the test, and not simply the access to the
test; TP53 germline testing for the risk of lethal—and mostly
unpreventable—malignancies is quite different from testing for a
predisposition to ear wax formation.
The “de-medicalizing” of cancer genetic testing is not a require-
ment for its increased uptake [69]. There is no question that cancer
predisposition testing will be more accessible in the future; it
remains to be determined how fast and to what extent it should be
de-medicalized. As has been shown, interpretation of variants,
indications for preventive surgeries, discussions of reproductive
options, to name a few, are aspects of this discipline not casually
considered. The issue is whether the “inevitable” future of cancer
genomics will be thrust upon society by commercial interests, or
whether that future course can be modulated in a responsible way
that protects the public health while implementing powerful new
medical tools for cancer prevention and early detection.Conﬂicts of interest
None.Acknowledgments
Supported by the Robert and Kate Niehaus Center for Inherited
Cancer Genomics, the Andrew Sabin Family Foundation, and theSharon Corzine Research Foundation. The views expressed are
those of the author and do not represent those of federal or
professional advisory groups on which he serves (National Cancer
Institute, Centers for Disease Control, American Society of Clinical
Oncology) or of Memorial Sloan Kettering Cancer Center. The
author would like to acknowledge Mark E. Robson, M.D. for his
invaluable insight and discussions.
References
[1] Stadler ZK, Schrader KA, Vijai J, Robson ME, Ofﬁt K. Cancer genomics and
inherited risk. J Clin Oncol 2014;32(7):687–98.
[2] Weitzel JN, Blazer KR, MacDonald DJ, Culver JO, Ofﬁt K. Genetics, genomics,
and cancer risk assessment: state of the art and future directions in the era of
personalized medicine. CA Cancer J Clin 2011;61(5):327–59.
[3] Ofﬁt K, Bradbury A, Storm C, Merz JF, Noonan KE, Spence R. Gene patents and
personalized cancer care: impact of the Myriad case on clinical oncology. J Clin
Oncol 2013;31(21):2743–8.
[4] Ofﬁt K. Personalized medicine: new genomics, old lessons. Hum Genet
2011;130(1):3–14.
[5] Kuhn TS. Thestructure of scientiﬁc revolutions. 3rd ed. Chicago, IL: University
of Chicago Press;1996.
[6] Shah S, Schrader KA, Waanders E, et al. A recurrent germline PAX5 mutation
confers susceptibility to pre-B cell acute lymphoblastic leukemia. Nat Genet
2013;45(10):1226–31.
[7] Topka S, Vijai J, Walsh MF, et al. Germline ETV6 mutations confer susceptibility
to acute lymphoblastic leukemia and thrombocytopenia. PLoS Genet 2015;11
(6):e1005262.
[8] Vijai J, Topka S, Villano D, et al. A recurrent ERCC3 truncating mutation confers
moderate risk for breast cancer. Cancer Disc 2016 [Epub ahead of print].
[9] Domchek SM, Bradbury A, Garber JE, Ofﬁt K, Robson ME. Multiplex genetic
testing for cancer susceptibility: out on the high wire without a net? J Clin
Oncol 2013;31(10):1267–70.
[10] Pollack A. After patent ruling, availability of gene tests could broaden. The New
York Times, Jun 13, 2013.
[11] Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene
sequencing panel for hereditary cancer risk assessment. J Clin Oncol 2014;32
(19):2001–9.
[12] Ofﬁt K, Garber JE. Time to check CHEK2 in families with breast cancer? J Clin
Oncol 2008;26(4):519–20.
[13] Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson
KL, et al. Gene-panel sequencing and the prediction of breast-cancer risk.
N Engl J Med 2015;372(23):2243–57.
[14] Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
Working Group. The EGAPP initiative: lessons learned. Genet Med 2014;16
(3):217–24.
[15] Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
Working Group. Recommendations from the EGAPP Working Group: does
the use of Oncotype DX tumor gene expression proﬁling to guide treatment
decisions improve outcomes in patients with breast cancer? Genet Med
2016;18(8):770–9.
[16] Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
Working Group. Recommendations from the EGAPP Working Group: can
K. Ofﬁt / Seminars in Oncology 43 (2016) 615–622 621UGT1A1 genotyping reduce morbidity and mortality in patients with meta-
static colorectal cancer treated with irinotecan? Genet Med 2009;11(1):15–20.
[17] Evaluation of Genomic Applications in Practice and Prevention (EGAPP)
Working Group. Recommendations from the EGAPP Working Group: genetic
testing strategies in newly diagnosed individuals with colorectal cancer aimed
at reducing morbidity and mortality from Lynch syndrome in relatives. Genet
Med 2009;11(1):35–41.
[18] Global Alliance for Genomics and Health [Internet]. 2016. Available from:
https://genomicsandhealth.org/work-products-demonstration-projects/brca-
challenge-0.
[19] Rehm HL, Berg JS, Brooks LD, et al. ClinGen—the clinical genome resource.
N Engl J Med 2015;372(23):2235–42.
[20] ClinGen - Clinical Genome Resource [Internet]. 2016. Available from: https://
clinicalgenome.org/about/working-groups/clinical-domain/cancer/.
[21] PROMPT PatientCrossroads [cited 2016 02/24/2016]. Available from: https://
connect.patientcrossroads.org/?org=prompt.
[22] Balmana J, Digiovanni L, Gaddam P, et al. Conﬂicting interpretation of genetic
variants and cancer risk by commercial laboratories as assessed by the
prospective registry of multiplex testing. J Clin Oncol 2016 [Epub ahead of
print].
[23] Gail Jarvik HR, Dan Roden. Panel 2: Consistency of interpretation of variants
across expert labs / groups, clinvar submissions? Genomic Medicine VIII
2015. Available from: https://www.genome.gov/Multimedia/Slides/GM8/
Panel2.pdf.
[24] Genetic Testing and Couseling Program: Cigna; [cited 2016]. Available
from: http://www.cigna.com/healthcare-professionals/resources-for-health-
care-professionals/genetic-testing-and-counseling-program.
[25] Lee J. Cigna to require counseling prior to some genetic tests. Modern
Healthcare 2013 Available from: http://www.modernhealthcare.com/article/
20130725/NEWS/307259958.
[26] New Cigna policy on cancer genetic testing poses risks to high quality cancer
care: ASCO; 2013. Available from: http://www.asco.org/advocacy/new-cigna-
policy-cancer-genetic-testing-poses-risks-high-quality-cancer-care.
[27] Zweig D. Aetna, Anthem and Cigna don’t cover genetic tests made popular by
‘Angelina effect’. FierceHealthPayer 2015 Available from: http://www.ﬁerce
healthpayer.com/story/aetna-anthem-and-cigna-dont-cover-genetic-tests-ma
de-popular-angelina-effec/2015-04-13.
[28] Bombard Y, Robson M, Ofﬁt K. Revealing the incidentalome when targeting
the tumor genome. JAMA 2013;310(8):795–6.
[29] Bombard Y, Bach PB, Ofﬁt K. Translating genomics in cancer care. J Natl Compr.
Cancer Netw 2013;11(11):1343–53.
[30] Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer
mutation discovery and interpretation. Sci Translat Med 2015;7(283) 283ra53.
[31] Zhang J, Walsh MF, Wu G, et al. Germline Mutations in Predisposition Genes in
Pediatric Cancer. N Engl J Med 2015;373(24):2336–46.
[32] Schrader KA, Cheng DT, Joseph V, et al. Germline variants in targeted tumor
sequencing using matched normal DNA. JAMA Oncol 2016;2(1):104–11.
[33] Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, et al. Diagnostic
Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children
With Solid Tumors. JAMA Oncol 2016;2(5):616–24.
[34] Mody RJ, Wu YM, Lonigro RJ, et al. Integrative clinical sequencing in the
management of refractory or relapsed cancer in youth. JAMA 2015;314
(9):913–25.
[35] Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in
men with metastatic prostate cancer. N Engl J Med 2016;375(5):443–53.
[36] Ofﬁt K. Clinical cancer genetics: risk counseling and management. New York:
Wiley; 1998.
[37] Couch FJ, Nathanson KL, Ofﬁt K. Two decades after BRCA: setting paradigms in
personalized cancer care and prevention. Science (New York, NY) 2014;343
(6178):1466–70.
[38] Daly MB, Pilarski R, Axilbund JE, et al. Genetic/familial high-risk assessment:
breast and ovarian, version 1.2014. J Natl Compr Cancer Netw 2014;12
(9):1326–38.
[39] Nelson HD, Fu R, Goddard K, et al. Risk assessment, genetic counseling, and
genetic testing for BRCA-related cancer: systematic review to update the US
Preventive Services Task Force Recommendation. U.S. Preventive Services Task
Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville
(MD) 2013.
[40] Force U.S.P.S.T. Genetic risk assessment and BRCA mutation testing for breast
and ovarian cancer susceptibility: recommendation statement. Ann Intern
Med 2005;143(5):355–61.
[41] King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and
BRCA2: 2014 Lasker Award. JAMA 2014;312(11):1091–2.
[42] Levy-Lahad E, Lahad A, King MC. Precision medicine meets public health:
population screening for BRCA1 and BRCA2. J Natl Cancer Inst 2015;107(1):420.
[43] Yurgelun MB, Hiller E, Garber JE. Population-wide screening for germline
BRCA1 and BRCA2 mutations: too much of a good thing? J Clin Oncol 2015;33
(28):3092–5.
[44] Neuhausen S, Gilewski T, Norton L, et al. Recurrent BRCA2 6174delT mutations in
Ashkenazi Jewish women affected by breast cancer. Nat Genet 1996;13(1):126–8.
[45] Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies
for common mutations in BRCA1 and BRCA2. Nat Genet 1996;14(2):185–7.
[46] Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1
185delAG mutation is approximately 1 percent in Ashkenazi Jewish individ-
uals. Nat Genet 1995;11(2):198–200.[47] Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2
6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
Nat Genet 1996;14(2):188–90.
[48] Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with
speciﬁc mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med
1997;336(20):1401–8.
[49] Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208
Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66
(4):1259–72.
[50] King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group. Breast
and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Science (New York, NY) 2003;302(5645):643–6.
[51] Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline
BRCA1 and BRCA2 mutations in a population series of 649 women with
ovarian cancer. Am J Hum Genet 2001;68(3):700–10.
[52] Hartman AR, Kaldate RR, Sailer LM, et al. Prevalence of BRCA mutations in an
unselected population of triple-negative breast cancer. Cancer 2012;118
(11):2787–95.
[53] Metcalfe KA, Poll A, Royer R, et al. A comparison of the detection of BRCA
mutation carriers through the provision of Jewish population-based genetic
testing compared with clinic-based genetic testing. Br J Cancer 2013;109
(3):777–9.
[54] Manchanda R, Loggenberg K, Sanderson S, et al. Population testing for cancer
predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a
randomized controlled trial. J Natl Cancer Inst 2015;107(1):379.
[55] Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer
incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin
Oncol 2014;32(15):1547–53.
[56] Gabai-Kapara E, Lahad A, Kaufman B, et al. Population-based screening for
breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S
A 2014;111(39):14205–10.
[57] Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1
and BRCA2 gene mutations in unselected Ashkenazi Jewish women with
breast cancer. J Natl Cancer Inst 1999;91(14):1241–7.
[58] Manchanda R, Legood R, Burnell M, et al. Cost-effectiveness of
population screening for BRCA mutations in Ashkenazi jewish women
compared with family history-based testing. J Natl Cancer Inst 2015;107(1):
380.
[59] Ofﬁt K. The BRCA gene and breast cancer. The New York Times. The Opinion
Pages, Letters. Oct 5, 2015.
[60] Regeneron launches 100k-patient genomics study with Geisinger, forms new
genetics center: GenomeWeb; 2014. Available from: https://www.genome
web.com/sequencing/regeneron-launches-100k-patient-genomics-study-gei
singer-forms-new-genetics-cent.
[61] Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacoge-
nomics: strategies and challenges. Nat Rev Genet 2013;14(1):23–34.
[62] Ofﬁt K, Robson ME. New pharmacogenomic paradigm in breast cancer treat-
ment. J Clin Oncol 2010;28(31):4665–6.
[63] Aminkeng F, Bhavsar AP. A coding variant in RARG confers susceptibility to
anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. 2015;47
(9):1079–84.
[64] Richards T, Montori VM, Godlee F, Lapsley P, Paul D. Let the patient revolution
begin. BMJ 2013;346:f2614.
[65] Shirts BH, Salama JS, Aronson SJ, et al. CSER and eMERGE: current and
potential state of the display of genetic information in the electronic health
record. J Am Med Inform Assoc 2015;22(6):1231–42.
[66] Prasad V, Fojo T, Brada M. Precision oncology: origins, optimism, and
potential. Lancet Oncol 2016;17(2):e81–6.
[67] Williams MS. Is the genomic translational pipeline being disrupted? Hum
Genom 2015;9:9.
[68] Ofﬁt K. Genomic proﬁles for disease risk: predictive or premature? JAMA
2008;299(11):1353–5.
[69] Ofﬁt K. Decade in review—genomics: a decade of discovery in cancer
genomics. Nat Rev Clin. Clin Oncol 2014;11(11):632–4.
[70] Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identiﬁes PALB2 as
a pancreatic cancer susceptibility gene. Science (New York, NY) 2009;324
(5924):217.
[71] Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary
pancreatic cancer. Cancer Disc 2012;2(1):41–6.
[72] Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, et al. Exome sequencing
identiﬁes MAX mutations as a cause of hereditary pheochromocytoma. Nat
Genet 2011;43(7):663–7.
[73] Mahamdallie SS, Hanks S, Karlin KL, et al. Mutations in the transcrip-
tional repressor REST predispose to Wilms tumor. Nat Genet 2015;47(12):
1471–4.
[74] Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause
primary lymphedema associated with a predisposition to acute myeloid
leukemia (Emberger syndrome). Nat Genet 2011;43(10):929–31.
[75] Saliba J, Saint-Martin C, Di Stefano A, et al. Germline duplication of ATG2B and
GSKIP predisposes to familial myeloid malignancies. Nat Genet 2015;47(10):
1131–40.
[76] Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF
predisposes to familial and sporadic melanoma. Nature 2011;480(7375):99–103.
[77] Horn S, Figl A, Rachakonda PS, et al. TERT promoter mutations in familial and
sporadic melanoma. Science 2013;339(6122):959–61.
K. Ofﬁt / Seminars in Oncology 43 (2016) 615–622622[78] Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to
malignant mesothelioma. Nat Genet 2011;43(10):1022–5.
[79] Farley MN, Schmidt LS, Mester JL, et al. A novel germline mutation in BAP1
predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 2013;
11(9):1061–71.
[80] Palles C, Cazier JB, Howarth KM, et al. Germline mutations affecting the
proofreading domains of POLE and POLD1 predispose to colorectal adenomas
and carcinomas. Nat Genet 2013;45(2):136–44.
[81] Weren RD, Ligtenberg MJ, Kets CM, et al. A germline homozygous mutation in
the base-excision repair gene NTHL1 causes adenomatous polyposis and
colorectal cancer. Nat Genet 2015;47(6):668–71.
[82] Gara SK, Jia L, Merino MJ, et al. Germline HABP2 mutation causing familial
nonmedullary thyroid cancer. N Engl J Med 2015;373(5):448–55.
[83] Park DJ, Lesueur F, Nguyen-Dumont T, et al. Rare mutations in XRCC2 increase
the risk of breast cancer. Am J Hum Genet 2012;90(4):734–9.[84] Park DJ, Odefrey FA, Hammet F, et al. FAN1 variants identiﬁed in multiple-case
early-onset breast cancer families via exome sequencing: no evidence for asso-
ciation with risk for breast cancer. Breast Cancer Res Treat 2011;130(3):1043–9.
[85] Ruark E, Snape K, Humburg P, et al. Mosaic PPM1D mutations are associated
with predisposition to breast and ovarian cancer. Nature 2013;493(7432):
406–410.
[86] Cybulski C, Carrot-Zhang J, Kluzniak W, et al. Germline RECQL mutations
are associated with breast cancer susceptibility. Nat Genet 2015;47(6):643–6.
[87] Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk
of ovarian cancer. Nat Genet 2011;43(11):1104–7.
[88] Noetzli L, Lo RW, Lee-Sherick AB, et al. Germline mutations in ETV6 are
associated with thrombocytopenia, red cell macrocytosis and predisposition
to lymphoblastic leukemia. Nat Genet 2015;47(5):535–8.
[89] Zhang MY, Churpek JE, Keel SB, et al. Germline ETV6 mutations in familial
thrombocytopenia and hematologic malignancy. Nat Genet 2015;47(2):180–5.
